News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Conference News VIVA 2021 Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms L.A. McKeown October 07, 2021
News Conference News VIVA 2020 As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice L.A. McKeown November 27, 2020
News Conference News VIVA 2019 Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions L.A. McKeown November 13, 2019
News Conference News VIVA 2019 Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel L.A. McKeown November 08, 2019
News Conference News VIVA 2019 Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee? L.A. McKeown November 06, 2019
News Conference News VIVA 2019 IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB L.A. McKeown November 05, 2019
News Conference News VIVA 2018 No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy L.A. McKeown November 13, 2018
News Conference News VIVA 2018 LUTONIX BTK: Hope for Challenging Patients at High Risk for Amputation L.A. McKeown November 07, 2018
News Conference News VIVA 2018 IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions L.A. McKeown November 06, 2018
News Conference News VIVA 2017 Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD L.A. McKeown September 18, 2017
Presentation VIVA 2017 Paclitaxel-Eluting Stent Treatment for PAD: Insights from the Zilver PTX Post-Market Study in Japan Presenter: Michael Dake September 14, 2017
News Conference News VIVA 2017 DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease L.A. McKeown September 13, 2017
News Conference News VIVA 2016 Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear L.A. McKeown September 21, 2016
News Conference News VIVA 2016 Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent L.A. McKeown September 20, 2016